$7.52
5.85%
Downside
Day's Volatility :12.59%
Upside
7.16%
43.88%
Downside
52 Weeks Volatility :63.9%
Upside
35.67%
Period | Orchestra Biomed Holdings Inc | Index (Russel 2000) |
---|---|---|
3 Months | 83.6% | 0.0% |
6 Months | 10.11% | 0.0% |
1 Year | 14.57% | 0.0% |
3 Years | -29.91% | -20.2% |
Market Capitalization | 289.9M |
Book Value | $1.6 |
Earnings Per Share (EPS) | -1.46 |
Wall Street Target Price | 16.33 |
Profit Margin | 0.0% |
Operating Margin TTM | -2326.29% |
Return On Assets TTM | -31.05% |
Return On Equity TTM | -65.81% |
Revenue TTM | 2.2M |
Revenue Per Share TTM | 0.06 |
Quarterly Revenue Growth YOY | -46.7% |
Gross Profit TTM | 0.0 |
EBITDA | -54.1M |
Diluted Eps TTM | -1.46 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.57 |
EPS Estimate Next Year | -1.69 |
EPS Estimate Current Quarter | -0.4 |
EPS Estimate Next Quarter | -0.4 |
What analysts predicted
Upside of 117.15%
FY20 | Y/Y Change | |
---|---|---|
Revenue | 5.7M | - |
Net Income | -21.4M | - |
Net Profit Margin | -374.45% | - |
FY21 | Y/Y Change | |
---|---|---|
Revenue | -782.0K | ↓ 113.71% |
Net Income | -23.0M | ↑ 7.77% |
Net Profit Margin | 2.9K% | ↑ 3317.42% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.5M | ↓ 551.79% |
Net Income | -33.6M | ↑ 46.03% |
Net Profit Margin | -951.26% | ↓ 3894.23% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.8M | ↓ 21.88% |
Net Income | -49.1M | ↑ 46.16% |
Net Profit Margin | -1.8K% | ↓ 828.45% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.1M | ↓ 5.16% |
Net Income | -876.7K | ↑ 27.84% |
Net Profit Margin | -79.49% | ↓ 20.52% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.2M | ↑ 5.53% |
Net Income | -10.9M | ↑ 1147.83% |
Net Profit Margin | -939.86% | ↓ 860.37% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 915.0K | ↓ 21.39% |
Net Income | -12.0M | ↑ 10.11% |
Net Profit Margin | -1.3K% | ↓ 376.64% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 419.0K | ↓ 54.21% |
Net Income | -13.3M | ↑ 10.54% |
Net Profit Margin | -3.2K% | ↓ 1861.54% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 262.0K | ↓ 37.47% |
Net Income | -12.8M | ↓ 3.74% |
Net Profit Margin | -4.9K% | ↓ 1714.33% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 620.0K | ↑ 136.64% |
Net Income | -13.5M | ↑ 5.03% |
Net Profit Margin | -2.2K% | ↑ 2720.92% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 38.1M | - |
Total Liabilities | 86.6M | - |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 13.5M | ↓ 64.49% |
Total Liabilities | 84.8M | ↓ 2.16% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 95.6M | ↑ 606.53% |
Total Liabilities | 43.0M | ↓ 49.22% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 95.2M | ↓ 0.38% |
Total Liabilities | 27.2M | ↓ 36.87% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 68.1M | ↓ 0.84% |
Total Liabilities | 7.3M | ↑ 4.31% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 136.3M | ↑ 100.19% |
Total Liabilities | 36.5M | ↑ 397.4% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 125.9M | ↓ 7.63% |
Total Liabilities | 36.4M | ↓ 0.23% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 116.4M | ↓ 7.57% |
Total Liabilities | 36.7M | ↑ 0.71% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 95.2M | ↓ 18.17% |
Total Liabilities | 27.2M | ↓ 25.97% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 82.6M | ↓ 13.22% |
Total Liabilities | 25.4M | ↓ 6.36% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -26.2M | - |
Investing Cash Flow | 27.0M | - |
Financing Cash Flow | 10.0M | - |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -19.4M | ↓ 25.8% |
Investing Cash Flow | 13.0M | ↓ 51.73% |
Financing Cash Flow | -4.0M | ↓ 139.93% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.7M | ↑ 1430.05% |
Investing Cash Flow | 8.1M | ↓ 3724.11% |
Financing Cash Flow | -5.1M | ↓ 94.5% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -14.4M | ↑ 64.47% |
Investing Cash Flow | 8.1M | ↑ 0.0% |
Financing Cash Flow | 56.8M | ↓ 1216.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.5M | ↓ 27.06% |
Investing Cash Flow | 8.1M | ↑ 0.0% |
Financing Cash Flow | 86.0K | ↓ 99.85% |
Sell
Neutral
Buy
Orchestra Biomed Holdings Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Orchestra Biomed Holdings Inc | 17.49% | 10.11% | 14.57% | -29.91% | -29.91% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Orchestra Biomed Holdings Inc | NA | NA | NA | -1.57 | -0.66 | -0.31 | NA | 1.6 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Orchestra Biomed Holdings Inc | Buy | $289.9M | -29.91% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Orchestra Biomed Holdings Inc
Revenue is up for the last 2 quarters, 262.0K → 620.0K (in $), with an average increase of 57.7% per quarter
Netprofit is down for the last 2 quarters, -12.81M → -13.46M (in $), with an average decrease of 5.0% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 47.0%
Organization | Orchestra Biomed Holdings Inc |
Employees | 56 |
CEO | Mr. David P. Hochman |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$7.52
-6.7%
Keyarch Acquisition Corp
$7.52
-6.7%
Connexa Sports Technologies Inc
$7.52
-6.7%
Us Value Etf
$7.52
-6.7%
First Wave Biopharma Inc
$7.52
-6.7%
Global X Msci Next Emerging
$7.52
-6.7%
Fat Projects Acquisition Corp
$7.52
-6.7%
Capital Link Global Fintech
$7.52
-6.7%
Applied Uv Inc
$7.52
-6.7%